HCW Biologics
HCWBHCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat chronic inflammation-driven diseases.
Table of contents
Earnings
Next report
Aug 7, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat chronic inflammation-driven diseases. The company leverages its proprietary TOBI and TRBC platforms to engineer multi-functional protein complexes designed to rebalance or rejuvenate the immune system. Its pipeline targets a broad range of conditions, including autoimmune disorders, cancer, and senescence-associated dysplasia.
A clinical-stage innovator utilizing proprietary protein engineering platforms to target the underlying mechanisms of chronic inflammation and senescence.
Questions, answered.
- What is HCW Biologics's market cap?
- HCW Biologics (HCWB) has a market capitalization of $4.0M and trades on NASDAQ.
- Who are HCW Biologics's competitors?
- HCW Biologics's key competitors include Amgen Inc., Bristol Myers Squibb Company, Coya Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does HCW Biologics partner with?
- HCW Biologics's notable partners include Beijing Trimmune Biotech Co., Ltd., Wugen Inc., ImmunityBio, Inc., and others.
- Where is HCW Biologics headquartered?
- HCW Biologics is headquartered in United States of America and employs approximately 45 people. It has been publicly traded since 2021.